Renal Denervation in Heart Failure with Preserved Ejection Fraction

肾去神经术治疗射血分数保留的心力衰竭

基本信息

批准号：
10836312
负责人：
Traci Taylor Goodchild
金额：
$ 81.16万
依托单位：
CEDARS-SINAI MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-03 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10836312
关键词：
Acetates Adult Aldosterone Angiotensin I Angiotensin II Animal Model Animals Attenuated Bilateral Biochemical Biological Markers Blood Pressure Monitors Blood Vessels Cardiac Cardiovascular system Catheters Cholesterol Chronic Clinical Conscious Coronary Coupled Denervation Deoxycorticosterone Development Devices Diabetes Mellitus Diagnosis Diet Disease Progression Down-Regulation EFRAC Endothelium FDA approved Fatty acid glycerol esters Fibrosis Fructose Functional disorder Genomics Harvest Heart Heart failure Histologic Hypertension Implant In Vitro Kidney Left Left ventricular structure Longevity Lung Measures Mediator Medical Medicine Metabolic Metabolic syndrome Mineralocorticoids Miniature Swine Morbidity - disease rate Myocardial Myocardial tissue Nerve Norepinephrine Obesity Organ Pathologic Pathology Patients Pharmacotherapy Physiologic intraventricular pressure Physiological Plasma Prevalence Proteomics Public Health Quality of life RNA Sequences Renal Tissue Renin Severities Signal Transduction Skeletal Muscle Sodium Chloride Stains Sympathetic Nervous System System Therapeutic Time Tissues Treadmill Tests Treatment Failure Tyrosine 3-Monooxygenase Ultrasonic Therapy Ventricular Work aging population candidate identification cardioprotection clinically relevant comorbidity cortical catecholamine density diabetic effective therapy exercise capacity exercise intolerance experimental study follow-up gene panel hemodynamics hypercholesterolemia hypertensive improved kidney cortex kidney dysfunction metabolomics mortality novel novel therapeutics porcine model pre-clinical preservation prevent protective effect radio frequency renal artery repaired sex therapeutic target ultrasound vascular injury western diet

项目摘要

PROJECT SUMMARY Heart failure with preserved ejection fraction (HFpEF) has emerged as a significant unmet medical need in cardiovascular medicine and 60% of all new heart failure diagnoses are HFpEF. The increasing prevalence of HFpEF coupled with a complete lack of effective FDA approved treatments further accentuates this critical public health problem. It is well appreciated that chronic over-activation of the sympathetic nervous system promotes left ventricular (LV) hypertrophic remodeling and fibrosis, profound endothelial and vascular injury, and renal dysfunction. The proposed studies will evaluate the beneficial effects of renal denervation (RDN) on left ventricular and vascular function in a novel swine model of HFpEF. HFpEF will be induced in Göttingen miniswine following chronic treatment with deoxycorticosterone acetate (DOCA) combined with a Western Diet that induces hypertension and metabolic syndrome followed by LV diastolic dysfunction, pulmonary congestion, exercise intolerance, and clinically relevant HFpEF. RDN will be performed following the onset of HFpEF utilizing a clinical RDN catheter system that employs ultrasound energy to destroy the renal sympathetic nerves. The Central Hypothesis of the proposed studies is that RDN therapy will promote myocardial repair and attenuate HFpEF progression via downregulation of pathological signaling in the kidney and heart. Specific Aim 1 is to determine the effects of RDN therapy on heart failure progression and severity in a clinically relevant large animal model of HFpEF. Specific Aim 2 is to identify candidate cardiac and extra-cardiac mediators that underlie the cardioprotective effects of RDN using genomic, metabolomic, and proteomic approaches. These studies will determine if RDN ameliorates the severity and progression of HFpEF and explore the mechanisms by which RDN exerts cardioprotective and vascular protective effects. These studies will involve an array of physiological, biochemical, genomic, metabolomic, and proteomic approaches to assess the potential efficacy of RDN in HFpEF. Results from these studies will significantly extend our current understanding of the pathobiology of HFpEF and provide critical information that helps to guide the development of novel therapies to treat patients that suffer from HFpEF.

项目摘要保留的射血分数（HFPEF）的心力衰竭已成为巨大的未满足的医疗需求心血管医学和所有新心力衰竭诊断的60％是HFPEF。越来越多的患病率 HFPEF加上完全缺乏有效的FDA批准的治疗，进一步加剧了这一关键公众健康问题。非常理解的是，交感神经系统的慢性过度激活会促进左心室（LV）肥厚性重塑和纤维化，深层内皮和血管损伤以及肾脏功能障碍。拟议的研究将评估肾脏神经（RDN）对左心室和 HFPEF的新型猪模型中的血管功能。 HFPEF将在GöttingenMiniswine中诱导用乙酸脱氧核心酮（DOCA）结合了影响影响的西方饮食的慢性治疗高血压和代谢综合征，然后进行LV舒张功能障碍，肺部充血，运动 intlerance和临床相关的HFPEF。 HFPEF开始使用临床，将进行RDN RDN导管系统采用超声能量来破坏肾交感神经。拟议研究的中心假设是RDN疗法将促进心肌修复并减弱 HFPEF通过下调肾脏和心脏中的病理信号传导而进展。具体目的1是确定RDN疗法对心力衰竭进展和严重程度的影响 HFPEF的临床相关大型动物模型。具体目的2是确定候选心脏和外心介体的基础使用基因组，代谢组和蛋白质组学方法对RDN的心脏保护作用。这些研究将确定RDN是否可以改善HFPEF的严重程度和进展，并探索 RDN执行心脏保护和血管保护作用的机制。这些研究将涉及物理，生化，基因组，代谢组和蛋白质组学方法评估潜力的阵列 RDN在HFPEF中的功效。这些研究的结果将大大扩展我们当前对 HFPEF的病理生物学，并提供关键信息，有助于指导新疗法的发展治疗患有HFPEF的患者。